Upcoming Roundup Trial Postponed: Bayer
Upcoming Roundup Trial Postponed: Bayer
Introduction
On Sunday, Bayer said in a statement, the upcoming trial date October 15, 2019, for Winston v. Monsanto in St. Louis City has been postponed with a court status conference in February 2020.
The Winston lawsuit, involving 14 plaintiffs, was filed in March 2018. The lawsuit is among the pending cases against Bayer claiming that exposure to the company’s glyphosate-based herbicide Roundup, caused them to develop Non-Hodgkin lymphoma, and the manufacturers deceived about the risks associated with it.
The lawsuit was the latest that had been set for trial in the St. Louis area, involving mediator Ken Feinberg, who is trying to negotiate a settlement between the company and U.S. plaintiffs. Judge Michael Mullen had scheduled the trial date for the lawsuit. According to a court document from the Circuit Court of the City of St. Louis, dated October 4, a status conference to reevaluate the case had been set for February 10.
Currently, Bayer is facing more than 18,400 claims, each involving similar allegations that Roundup causes Non-Hodgkin's lymphoma and other cancers. Roundup lawsuits are consolidated under federal multidistrict litigation (MDL No. 2741; In Re: Roundup Products Liability Litigation) in the Northern District of California, presided by U.S. District Judge Vince Chhabria.
Comments
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Categories: Opioids
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…